Live webcasts of the presentations will be available on the News & Events – Events page of Jasper's Investor Relations website. An archived replay of each presentation will be available on Jasper's ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Jasper Therapeutics (JSPR – Research Report) and ...

Live webcasts of the presentations will be available on the News & Events – Events page of Jasper's Investor Relations website. An archived replay of each presentation will be available on ...

Jasper Therapeutics, Inc. (NASDAQ:JSPR) is a clinical-stage biotechnology company focused on developing novel therapies for hematopoietic stem cell transplantation and mast cell-mediated diseases.

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Free Report) have earned an average rating of “Buy” from the eleven analysts that are covering the company, Marketbeat reports.

Jasper Therapeutics, Inc. (NASDAQ:JSPR) is a clinical-stage biotechnology company focused on developing novel therapies for hematopoietic stem cell transplantation and mast cell-mediated diseases. The ...

REDWOOD CITY, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel ...

Fintel reports that on February 13, 2025, UBS initiated coverage of Jasper Therapeutics (NasdaqCM:JSPR) with a Buy recommendation. Analyst Price Forecast Suggests 1,084.43% Upside As of January 29 ...

Jasper Therapeutics, Inc., a biotechnology company focused on developing briquilimab, an antibody therapy for mast cell-driven diseases, announced several presentations related to briquilimab at ...

(MENAFN- GlobeNewsWire - Nasdaq) REDWOOD CITY, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage ...